Moors & Cabot, Inc. Astrazeneca PLC Transaction History
Moors & Cabot, Inc.
- $1.85 Billion
- Q2 2024
A detailed history of Moors & Cabot, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Moors & Cabot, Inc. holds 7,070 shares of AZN stock, worth $531,805. This represents 0.03% of its overall portfolio holdings.
Number of Shares
7,070
Previous 8,435
16.18%
Holding current value
$531,805
Previous $571,000
3.5%
% of portfolio
0.03%
Previous 0.03%
Shares
32 transactions
Others Institutions Holding AZN
# of Institutions
1,343Shares Held
492MCall Options Held
4.99MPut Options Held
3.19M-
Price T Rowe Associates Inc Baltimore, MD64.9MShares$4.88 Billion0.61% of portfolio
-
Primecap Management CO Pasadena, CA42.6MShares$3.2 Billion2.44% of portfolio
-
Wellington Management Group LLP Boston, MA40.6MShares$3.05 Billion0.58% of portfolio
-
Capital International Investors Los Angeles, CA36.7MShares$2.76 Billion0.6% of portfolio
-
Franklin Resources Inc San Mateo, CA17.6MShares$1.32 Billion0.44% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $233B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...